In case you missed it, psychedelic medical research in the US just got a $17m injection from private donors.
The research will centralise around psychedelic compounds such as psilocybin, which is the hallucinogenic compound found in ‘magic mushrooms’.
Researchers at the newly funded Johns Hopkins Centre for Psychedelic Research will assess the potential for psychedelic treatments for an array of medical conditions including depression, opiod addiction, anorexia and PTSD to name a few.
Previous psychadelic research conducted on volunteering cancer patients has displayed hugely promising results for these treatments. Studies have shown that high dose psylocybin experiences are able to reduce depression and anxiety and an increase in quality of life, life meaning and optimism.
The perplexing thing is that these effects seem to last for months. This sustained improvement in mindset and increase in mental plasticity has massive theraputic implications if the research concludes that the compounds are safe for clinical use. Which, with this funding, could easily occur within the next decade.
Whether you’re invested and interested in this research, or you’ve never heard of psylocybin before, this announcement panel is worth a watch.